Effectiveness and safety of recombinant zoster vaccine : A review of real-world evidence
The recombinant zoster vaccine (RZV) was licensed in the US for prevention of herpes zoster (HZ) in 2017. We conducted a literature search (January 1, 2017-August 1, 2023) using PubMed, Embase, and Scopus to consolidate the real-world evidence related to RZV. Overall, RZV effectiveness against HZ was high across the studied populations in real-world settings, including adults aged ≥ 50 years and patients aged ≥ 18 years with immunodeficiency or immunosuppression. Effectiveness was higher with two doses versus one dose, especially in elderly people and immunocompromised individuals. The safety profile of RZV was broadly consistent with that established in clinical trials. RZV does not appear to increase the risk of disease flares in patients with immune-mediated diseases. Approximately two-thirds of individuals received a second RZV dose within 2-6 months after the first dose. Collectively, RZV effectiveness against HZ was high, and these real-world studies reaffirm its favorable benefit-risk profile.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 19(2023), 3 vom: 15. Dez., Seite 2263979 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parikh, Raunak [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.11.2023 Date Revised 19.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2023.2263979 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364588403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364588403 | ||
| 003 | DE-627 | ||
| 005 | 20231226211157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2023.2263979 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1215.xml |
| 035 | |a (DE-627)NLM364588403 | ||
| 035 | |a (NLM)37967254 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parikh, Raunak |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and safety of recombinant zoster vaccine |b A review of real-world evidence |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.11.2023 | ||
| 500 | |a Date Revised 19.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The recombinant zoster vaccine (RZV) was licensed in the US for prevention of herpes zoster (HZ) in 2017. We conducted a literature search (January 1, 2017-August 1, 2023) using PubMed, Embase, and Scopus to consolidate the real-world evidence related to RZV. Overall, RZV effectiveness against HZ was high across the studied populations in real-world settings, including adults aged ≥ 50 years and patients aged ≥ 18 years with immunodeficiency or immunosuppression. Effectiveness was higher with two doses versus one dose, especially in elderly people and immunocompromised individuals. The safety profile of RZV was broadly consistent with that established in clinical trials. RZV does not appear to increase the risk of disease flares in patients with immune-mediated diseases. Approximately two-thirds of individuals received a second RZV dose within 2-6 months after the first dose. Collectively, RZV effectiveness against HZ was high, and these real-world studies reaffirm its favorable benefit-risk profile | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Autoimmune disease | |
| 650 | 4 | |a completion rate | |
| 650 | 4 | |a effectiveness | |
| 650 | 4 | |a herpes zoster | |
| 650 | 4 | |a immunodeficiency | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a post-herpetic neuralgia | |
| 650 | 4 | |a real-world evidence | |
| 650 | 4 | |a recombinant zoster vaccine | |
| 650 | 4 | |a safety | |
| 650 | 7 | |a Herpes Zoster Vaccine |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 700 | 1 | |a Singer, David |e verfasserin |4 aut | |
| 700 | 1 | |a Chmielewski-Yee, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Dessart, Christophe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 19(2023), 3 vom: 15. Dez., Seite 2263979 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:3 |g day:15 |g month:12 |g pages:2263979 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2023.2263979 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 3 |b 15 |c 12 |h 2263979 | ||